The role of crystallography in drug design

AAPS Journal

Volumn 7, Issue 4, 2005, Pages

  Deschamps, Jeffrey R ^a  

^a NAVAL RESEARCH LABORATORY   (United States)

Author keywords

Absolute configuration; Opioid; Pharmacophore; Structure; X ray diffraction

Indexed keywords

BENZOMORPHAN DERIVATIVE; BIPHALIN; BUPRENORPHINE; DELTAKEPHALIN; DEXTRO ALANINE ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2 DEXTRO PENICILLAMINE 5 PENICILLAMINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETORPHINE; LEVO ALANINE ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; METKEPHAMIDE; MORPHINE; OPIATE AGONIST; OPIATE PEPTIDE; UNCLASSIFIED DRUG;

ACCURACY; ANALGESIC ACTIVITY; ARTICLE; BRADYCARDIA; CHIRALITY; DIZZINESS; DRUG DEPENDENCE; DRUG DESIGN; DRUG STRUCTURE; ENANTIOSELECTIVITY; HUMAN; NAUSEA AND VOMITING; NONHUMAN; PAIN; PHARMACOPHORE; RESPIRATION DEPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SWEATING; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; CRYSTALLOGRAPHY; METHODOLOGY; SWINE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY; DRUG DESIGN; OPIOID PEPTIDES; SWINE;

EID: 33747141167     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070478     Document Type: Article

References (44)

1. Griffin JF, Duax WL, eds. Molecular Structure and Biological Activity. New York, NY: Elsevier Biomedical; 1982.
2. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of 2 related pentapeptides from brain with potent opiate agonist activity. Nature. 1975;258:577-579.
3. Temussi PA, Picone D, Castiglione-Morelli MA, Motta A, Tancredi T. Bioactive conformation of linear peptides in solution: an elusive goal. Biopolymers. 1989;28:91-107.
4. Karle IL, Karle J, Mastropaolo D, Camerman A, Camerman N. [Leu-5]enkepalin - 4 co-crystallizing conformers with extended backbones that form an anti-parallel beta-sheet. Acta Crystallogr. 1983;B39:625-637.
5. Smith D, Griffin JF. Conformation of [Leu-5]enkephalin rrom X-ray-diffraction: features important for recognition at opiate receptor. Science. 1978;199:1214-1216.
6. Aubry A, Birlirakis N, Sakarellos-Daitsiotis M, Sakarellos C, Marraud M. A crystal molecular-conformation of leucine-enkephalin related to the morphine molecule. Biopolymers. 1989;28:27-40.
7. 5]enkephalins: formation of a dimeric antiparallel beta-structure. J Biochem (Tokyo). 1987;101:485-490.
8. Loew GH. Molecular modeling of opioid analgesics. Mod Drug Discovery. 1999;2:24-30.
9. SHELXTL [Computer program]. Version 6.10. Madison, Wisconsin: Bruker AXS Inc. 2000.
10. 5] enkephalin: observations of a novel pleated β-sheet. Proc Natl Acad Sci USA. 1986;83:3272-3276.
11. Deschamps JR, Flippen-Anderson JL, Brine GA, Hayes JP, George C. Boc-tyrosyl-D-alanyl-glycyl-Nmethyl-pnenylalanyl-O-methyl-methionine hydrate: a protected analog of metkephamid. Acta Crystallogr. 2002;58E.o13-o15.
12. 5] enkephalin. Biochem J. 1984;218:677-689.
13. 3H]: an active synthetic enkephalin analog. J Chem Soc Chem Comm. 1985;11:681-682.
14. 5]-enkephalin (DADLE). Acta Crystallogr. 1996; 52:1583-1585.
15. Flippen-Anderson JL, Deschamps JR, Ward KB, George C, Houghten R. The crystal structure of deltakephalin: a δ-selective opioid peptide with a novel β-bend-like conformation. Int J Pept Protein Res. 1994; 44:97-104.
16. 1H NMR spectroscopy. Biochem Biophys Res Commun. 1977;79.1199-1206.
17. Flippen-Anderson JL, Deschamps JR, George C, Hruby VJ, Misicka A, 'Lipkowski AW. Crystal structure of biphalin - multireceptor opioid peptide. J Pept Res. 2002;59:123-133.
18. Flippen-Anderson JL, George C, Deschamps JR, Reddy PA, Lewin AH, Brine GA. X-ray structures of a potent δ-receptor selective opioid antagonist and a protected form of the δ-receptor antagonist ICI 174,864. Lett Pept Sci. 1994;1:107-115.
19. 5] enkephalin, a highly potent, delta-opioid receptor-selective compound: comparisons with proposed solution conformations. J Am Chem Soc. 1994; 116:7523-7531.
20. 3]DPDPE. J Am Chem Soc. 1996; 118:2143-2152.
21. 5): novel conformationally constrained opioid peptides. J Am Chem Soc. 1996; 118:959-969.
22. 1H-NMR data. J Am Chem Soc. 1994;116:429-436.
23. 2), a highly potent μ-receptor selective opioid agonist: comparisons with proposed model structures. J Pept Res. 1997;49:384-393.
24. Ciajolo MR, Balboni G, Picone D, et al. A solution and solid-state structure of the diketopiperazine of tyrosyl-tetrahydroisoquinoline-3-carboxylic acid. Int J Pept Protein Res. 1995;46:134-138.
25. Deschamps JR, Flippen-Anderson JL, George C. 2-[N-(t-Butoxycarbonyl)tyrosyl] -1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid nitromethane solvate, Acta Crystallogr. 2001;57E:o87-o90.
26. Deschamps JR, Flippen-Anderson JL, Moore C, Cudney R, George C. Tyrosyl-D-tetrahydroisoquinoline3-carboxylic acid and tyrosyl-D-tetrahydroisoquinoline-3-carboxamide. Acta Crystallogr. 1997;C53:1478-1482.
27. Bryant SD, George C, Flippen-Anderson JL, et al. Crystal structures of dipeptides containing the DMT-TIC pharmacophore. J Med Chem. 2002;45:5506-5513.
28. Petsko GA. On the other hand.... Science. 1992;256:1403-1404.
29. Milton RC, Milton SCF, Kent BBH. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show demonstration of reciprocal chiral substrate specificity. Science. 1992;256:1445-1448.
30. Coster D, Knol KS, Prins JA. Unterschiede in der intensität der röntgenstrahlen-feflexion an den beiden 111-flächen der zinkblende. Z Phys. 1930;63:345-369.
31. Bijvoet JM, Peerdeman AF, van Bommel AJ. Determination of the absolute configuration of optically active compounds by means of X-rays. Nature. 1951;168:271-272.
32. Flack HD. On enantiomorph-polarity estimation. Acta Crystallogr. 1983;A39:876-881.
33. Schiller PW, Nguyen TMD, Weltrowska G, et al. Differential stereochemical requirments of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc Natl Acad Sci USA. 1992;89:11871-11875.
34. Balboni G, Guerrini R, Salvadori S, et al. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem. 2002;45:713-720.
35. Eddy NB, May EL. The search for a better analgesic. Science. 1973;181:407-414.
36. Schiller PW, Yam CF, Lis M. Evidence of topographical analogy between methionine-enkephalin and morphine derivatives, Biochemistry. 1977; 16:1831-1838.
37. Gylbert L. The crystal and molecule structure of morphine hydrochloride trihydrate. Acta Crystallogr. 1973;B29:1630-1635.
38. Thomas G. Medicinal Chemistry. An Introduction. Chichester, UK: John Wiley & Sons; 2000.
39. Foye WO, Lemke TL, Williams DA. Principles of Medicinal Chemistry. Baltimore, MD: Williams & Wilkins; 1995.
40. Michel AG, Evrard G, Norberg B, Milchert E. Molecular-Structure of Opiate Alkaloids. 2. Crystal-Structures of 4-Methylhomobenzomorphan Hydrobromide (I) and 4,12-beta-Dimethylhomobenzomorphan (II). Can J Chem. 1988;66:1763-1769.
41. Thomas JB, Zheng XL, Mascarella SW, et al. N-substituted 9β-methyl-5-(3-hyroxyphenyl)morphans are opioid receptor pure antagonists. J Med Chem. 1998;41:4143-4149.
42. Hashimoto A, Jabobson AE, Rothman RB, et al. Probes for narcotic receptor mediated phenomena. 28. New opioid antagonists from enantiomeric analogues of m-hydroxyphenyl-N-phenylethylmorphan. Bioorg Med Chem. 2002;10:3319-3329.
43. Flippen-Anderson JL, George C, Bertha CM, Rice KC. X-ray crystal structures of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine. Heterocycles. 1994;39:751-766.
44. Hruby VJ, Gehrig CA. Recent developments in the design of receptor specifico-peptides. Med Res Rev. 1989;9:343-401.